🧾 What This Document Is

This is an 8-K filing, which is a "current report" companies file with the SEC to announce major events that shareholders should know about. Think of it as a breaking news alert for investors.

This specific filing is packed with three big announcements:

A corporate acquisition: Shareholders approved selling Aptose to Hanmi Pharmaceutical.
Clinical trial results: New data on their lead cancer drug.
Annual financial results: How the company performed financially for 2025.

👉 Why it matters: This document signals a major transition for Aptose. It's going from a public company to a private one owned by Hanmi, while also showing promising progress on its key drug.

🏢 What The Company Does

In simple terms, Aptose Biosciences is a cancer drug developer. They are a "clinical-stage" biotech company, meaning they're focused on researching and testing new drugs but aren't selling any yet.

Their main focus is on a drug called tuspetinib (TUS). They are developing it as a new, frontline (first-line) treatment for patients just diagnosed with a aggressive blood cancer called acute myeloid leukemia (AML). Their approach is to combine TUS with two other existing drugs (venetoclax and azacitidine) into a three-drug "triplet" therapy.

🤝 The Deal: Going Private with Hanmi

This is the most significant event in the filing. Aptose will be acquired by Hanmi Pharmaceutical, a large South Korean pharmaceutical company, in a "go-private" transaction.

What's happening: Hanmi, which already owned a significant stake and had provided over US$41 million in loans to Aptose, will now buy all the remaining shares it doesn't already own.
The price: Each Aptose shareholder (other than Hanmi) will receive C$2.41 in cash per share. This was a 28% premium over the stock's recent average price.
The vote: At a special meeting, over 91% of shareholders voted in favor of the deal.
What's next: A court has already approved the deal. It is expected to close by the end of April 2026, pending final regulatory checks.

👉 Why it matters: Aptose gets a committed, deep-pocketed partner in Hanmi to fund the expensive final stages of drug development. For shareholders, it provides a clear exit at a premium price.

🧪 Pipeline & Clinical Trial Data

The filing highlights positive early results for their key drug combination, TUS + venetoclax + azacitidine, in newly diagnosed AML patients.

Effectiveness: The therapy showed high response rates. 90% of patients across different dose levels had a strong clinical response. At higher doses, this was 100%.
Deep remissions: A crucial sign of deep treatment success, called MRD negativity (no detectable cancer cells), was seen in 78% of responding patients.
Safety: The treatment was well-tolerated. There were no dose-limiting toxicities, no treatment-related deaths, and no severe side effects like prolonged blood count suppression or heart rhythm issues.
Broad promise: The positive effects were seen in patients with various genetic mutations, making the treatment potentially "mutation agnostic" (effective regardless of specific genetic markers).

👉 Why it matters: Strong early-stage data like this is the fuel for a biotech company's value. It shows the drug has real potential, which explains Hanmi's confidence in acquiring and funding Aptose to advance it.

💰 Financial Highlights & Position

Here’s a snapshot of Aptose's finances for the year ended December 31, 2025 (all numbers in thousands of USD):

Net Loss: $25.5 million, similar to the $25.4 million loss in 2024.
Cash on Hand: $4.1 million as of year-end. The company explicitly states it does not have enough cash to fund operations and relies on advances from Hanmi to keep going.
The Debt: A key change is the large increase in long-term liabilities, from $10.2 million in 2024 to $27.9 million in 2025. This reflects the debt owed to Hanmi.
R&D Spending: Costs decreased to $11.3 million from $15.1 million the year before, primarily due to lower spending on their tuspetinib program as some trials concluded.

👉 Why it matters: The financials show a typical clinical-stage biotech profile: operating at a loss, cash-constrained, and dependent on a funding partner. This financial pressure is a key reason the acquisition by Hanmi makes strategic sense.

🔮 What's Next

Close the Hanmi Acquisition: The primary near-term goal is to complete the sale to Hanmi by the end of April 2026. Once done, Aptose will no longer be a publicly traded company.
Advance the TUS Triplet Therapy: With Hanmi's full backing, the focus will be on further developing the TUS+VEN+AZA combination. The next data update is scheduled for the EHA2026 Congress in June 2026.
Present More Data: The company mentions preliminary findings from the highest (160 mg) dose level showing early promise, which will be shared in future presentations.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Promising Drug Data: The TUS triplet shows high efficacy and a manageable safety profile in early trials.
Strong, Committed Partner: Hanmi Pharmaceutical is providing both the acquisition capital and the ongoing R&D funding needed to advance the drug.
Clear Path Forward: The go-private transaction removes the pressure of being a public company and secures long-term financial backing.

⚠️ Risks:

Development Remains Early: The drug is still in clinical trials. Much larger and longer studies are needed to prove it is safe and effective enough for final regulatory approval.
Regulatory Hurdles: The acquisition still requires final regulatory approvals. Any unforeseen issues could delay or derail the deal.
Competition: The AML treatment landscape is competitive. Other companies are developing new therapies.

🧠 The Analogy

This acquisition is like a promising indie game studio with a hit prototype getting fully acquired by a major publisher (Hanmi). The studio gets the massive funding and resources it needs to turn the prototype into a full, globally released game, while the original investors (shareholders) get a buyout at a premium price.

📇 Key Contacts & People

William G. Rice, Ph.D.: Chairman, President and Chief Executive Officer
Susan Pietropaolo: Corporate Communications & Investor Relations
- Phone: 201-923-2049
- Email: [email protected]

🧩 Final Takeaway

Aptose Biosciences is being acquired by Hanmi Pharmaceutical in a deal approved by shareholders, providing a cash exit and securing the funding to advance its promising leukemia drug, which showed strong early clinical trial results. The company will transition from a cash-strapped public entity to a privately funded subsidiary focused on drug development.

Aptose Biosciences Inc. — 8-K Filing